Fidelity Investments’s ACELYRIN SLRN Stock Holding History

Fidelity Investments’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,976	Closed	-$12.3K	–	5488
2025 Q1	$12.3K	Sell	4,976 -159,335	-97%	-$379K	﹤0.01%	4428
2024 Q4	$516K	Buy	164,311 +46,563	+40%	+$225K	﹤0.01%	2915
2024 Q3	$580K	Sell	117,748 -4,596,424	-98%	-$23.7M	﹤0.01%	2797
2024 Q2	$20.8M	Sell	4,714,172 -2,365,038	-33%	-$11.1M	﹤0.01%	1639
2024 Q1	$47.8M	Sell	7,079,210 -1,743,061	-20%	-$13.2M	﹤0.01%	1345
2023 Q4	$65.8M	Sell	8,822,271 -139,455	-2%	-$1.19M	0.01%	1181
2023 Q3	$89.9M	Buy	8,961,726 +1,505,488	+20%	+$32M	0.01%	1024
2023 Q2	$151M	Buy	+7,456,238	New	+$152M	0.01%	834

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fidelity Investments's SLRN Position: Q2 2025 in Review

Fidelity Investments sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 4,976 shares — an estimated $12.3K sold.

Fidelity Investments first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $151M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Fidelity Investments reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Fidelity Investments sold 4,976 ACELYRIN shares in Q2 2025, an estimated $12.3K.
Fidelity Investments first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Fidelity Investments's ACELYRIN position peaked at $151M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.